Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Barnes

Showing results (231-240 of 442) with videos related to

Pageof 45
Sort By:
Journal of Medical Education|June 1, 1987
Residents' attitudes, knowledge, and behavior regarding diagnosis and treatment of alcoholismM M Warburg, P D Cleary, M Rohman, et al.
BMC Pulmonary Medicine|May 13, 2020
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysisJames F Donohue, Edward Kerwin, Chris N Barnes, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|January 29, 2020
Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5-Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding IntoleranceMarianne J Chapman, Karen L Jones, Cristina Almansa, et al.
Pulmonary Pharmacology & Therapeutics|June 2, 2019
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trialsJames F Donohue, Gregory Feldman, Sanjay Sethi, et al.
Vascular Medicine (London, England)|August 1, 2012
Contribution of blood viscosity in the assessment of flow-mediated dilation and arterial stiffnessKristin L Parkhurst, Hsin-Fu Lin, Allison E Devan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2020
Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major MetaboliteDavid L Bourdet, Suresh Yeola, Sharath S Hegde, et al.
Physiological Reports|October 28, 2014
Acute cyclooxygenase inhibition does not alter muscle sympathetic nerve activity or forearm vasodilator responsiveness in lean and obese adultsJill N Barnes, Nisha Charkoudian, Luke J Matzek, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|May 17, 2008
Interrelationships among noninvasive measures of postischemic macro- and microvascular reactivityMandeep Dhindsa, Shawn M Sommerlad, Allison E DeVan, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|October 25, 2019
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow RateDonald A Mahler, Jill A Ohar, Chris N Barnes, et al.
Frontiers in Physiology|June 16, 2012
Association of cardiac baroreflex sensitivity with blood pressure transients: influence of sex and menopausal statusJill N Barnes, Luke J Matzek, Nisha Charkoudian, et al.
Pageof 45

Showing results (231-240 of 442) with videos related to

Sort By:
Pageof 45
Journal of Medical Education|June 1, 1987
Residents' attitudes, knowledge, and behavior regarding diagnosis and treatment of alcoholismM M Warburg, P D Cleary, M Rohman, et al.
BMC Pulmonary Medicine|May 13, 2020
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysisJames F Donohue, Edward Kerwin, Chris N Barnes, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|January 29, 2020
Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5-Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding IntoleranceMarianne J Chapman, Karen L Jones, Cristina Almansa, et al.
Pulmonary Pharmacology & Therapeutics|June 2, 2019
Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trialsJames F Donohue, Gregory Feldman, Sanjay Sethi, et al.
Vascular Medicine (London, England)|August 1, 2012
Contribution of blood viscosity in the assessment of flow-mediated dilation and arterial stiffnessKristin L Parkhurst, Hsin-Fu Lin, Allison E Devan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2020
Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major MetaboliteDavid L Bourdet, Suresh Yeola, Sharath S Hegde, et al.
Physiological Reports|October 28, 2014
Acute cyclooxygenase inhibition does not alter muscle sympathetic nerve activity or forearm vasodilator responsiveness in lean and obese adultsJill N Barnes, Nisha Charkoudian, Luke J Matzek, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|May 17, 2008
Interrelationships among noninvasive measures of postischemic macro- and microvascular reactivityMandeep Dhindsa, Shawn M Sommerlad, Allison E DeVan, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|October 25, 2019
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow RateDonald A Mahler, Jill A Ohar, Chris N Barnes, et al.
Frontiers in Physiology|June 16, 2012
Association of cardiac baroreflex sensitivity with blood pressure transients: influence of sex and menopausal statusJill N Barnes, Luke J Matzek, Nisha Charkoudian, et al.
Pageof 45